Health In Tech (HIT)
Market Price (11/1/2026): $0 | Market Cap: $-Sector: Information Technology | Industry: Application Software
Health In Tech (HIT)
Market Price (11/1/2026): $0Market Cap: $-Sector: Information TechnologyIndustry: Application Software
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -18% Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -55% Megatrend and thematic driversMegatrends include Digital Health & Telemedicine. Themes include Telehealth Platforms, Health Data Analytics, and AI in Healthcare Management. | Weak multi-year price returns2Y Excs Rtn is -122%, 3Y Excs Rtn is -174% | Penny stockMkt Price is 0.6 Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -5.3 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -16% Weak revenue growthRev Chg QQuarterly Revenue Change % is -13% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -16%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -23% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -15% Key risksHIT key risks include [1] execution and scalability challenges amid its accelerated growth phase and [2] a demonstrated vulnerability to potential reductions in federal healthcare spending. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -18% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -55% |
| Megatrend and thematic driversMegatrends include Digital Health & Telemedicine. Themes include Telehealth Platforms, Health Data Analytics, and AI in Healthcare Management. |
| Weak multi-year price returns2Y Excs Rtn is -122%, 3Y Excs Rtn is -174% |
| Penny stockMkt Price is 0.6 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -5.3 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -16% |
| Weak revenue growthRev Chg QQuarterly Revenue Change % is -13% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -16%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -23% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -15% |
| Key risksHIT key risks include [1] execution and scalability challenges amid its accelerated growth phase and [2] a demonstrated vulnerability to potential reductions in federal healthcare spending. |
Qualitative Assessment
AI Analysis | Feedback
Health In Tech (HIT) stock has lost about 50% since 7/31/2026 because of the following key factors:
1. Significant Downward Revision of Full-Year 2026 Revenue Guidance.
Health In Tech dramatically revised its full-year fiscal 2026 revenue outlook in late Q3 2026, slashing it to approximately $33 million, a reduction of 27% to 34% from its earlier projection. Previously, in fiscal Q4 2025, the company had anticipated full-year 2026 revenue to be in the range of $45 million to $50 million, representing year-over-year growth of approximately 35% to 50%. This substantial downgrade was attributed primarily to the timing of the commercialization of its HitRix platform, its Three-Year Rate Stabilization Program, and issues with additional carrier capacity, which impacted the timing of new policy effective dates and associated revenue recognition.
2. Weak Second Quarter Fiscal 2026 Financial Performance.
The company reported disappointing financial results for fiscal Q2 2026 (ended June 30, 2026), with revenue falling to $8.1 million from $9.3 million in fiscal Q2 2025. Health In Tech also swung to a net loss of $2.5 million, or $(0.04) per diluted share, in fiscal Q2 2026, compared to a net income of $0.6 million in the prior year's second quarter. Despite reaffirming its original full-year revenue guidance at the time of the Q2 report, these declining revenues and a return to unprofitability likely eroded investor confidence leading into the subsequent guidance reduction.
Show more
Health In Tech (HIT) stock has lost about 50% since 7/31/2026 because of the following key factors:
1. Significant Downward Revision of Full-Year 2026 Revenue Guidance.
Health In Tech dramatically revised its full-year fiscal 2026 revenue outlook in late Q3 2026, slashing it to approximately $33 million, a reduction of 27% to 34% from its earlier projection. Previously, in fiscal Q4 2025, the company had anticipated full-year 2026 revenue to be in the range of $45 million to $50 million, representing year-over-year growth of approximately 35% to 50%. This substantial downgrade was attributed primarily to the timing of the commercialization of its HitRix platform, its Three-Year Rate Stabilization Program, and issues with additional carrier capacity, which impacted the timing of new policy effective dates and associated revenue recognition.
2. Weak Second Quarter Fiscal 2026 Financial Performance.
The company reported disappointing financial results for fiscal Q2 2026 (ended June 30, 2026), with revenue falling to $8.1 million from $9.3 million in fiscal Q2 2025. Health In Tech also swung to a net loss of $2.5 million, or $(0.04) per diluted share, in fiscal Q2 2026, compared to a net income of $0.6 million in the prior year's second quarter. Despite reaffirming its original full-year revenue guidance at the time of the Q2 report, these declining revenues and a return to unprofitability likely eroded investor confidence leading into the subsequent guidance reduction.
3. Broader Health Technology Sector Headwinds and Regulatory Scrutiny.
The broader health technology sector, particularly in areas involving AI, faced significant challenges throughout 2026. The industry has seen an estimated 85% failure rate for HealthTech startups, with a median lifespan of 5.2 years. This challenging environment is marked by regulatory complexity, extended sales cycles, and "science risk." The "healthcare AI bubble" has reportedly been bursting in 2026, due to issues such as the "zombie algorithm phenomenon" where static AI models fail as the healthcare environment evolves, difficulties in integrating AI with legacy electronic health record (EHR) systems, and rising professional liability premiums for AI-assisted medical practices. Additionally, in fiscal Q4 2026, CMS leaders warned that applying AI to a fragmented healthcare system would lead to "faster fragmentation and more efficient bureaucracy," indicating a difficult and highly scrutinized operating environment for AI-enabled InsurTech platforms like Health In Tech.
Show less
Stock Movement Drivers
Fundamental Drivers
The -48.0% change in HIT stock from 7/31/2026 to 10/31/2026 was primarily driven by a -40.8% change in the company's P/S Multiple.| (LTM values as of) | 7312026 | 10312026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.11 | 0.58 | -48.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 34 | 33 | -3.7% |
| P/S Multiple | 1.9 | 1.1 | -40.8% |
| Shares Outstanding (Mil) | 57 | 63 | -8.7% |
| Cumulative Contribution | -48.0% |
Market Drivers
7/31/2026 to 10/31/2026| Return | Correlation | |
|---|---|---|
| HIT | -48.0% | |
| Market (SPY) | 1.2% | 18.5% |
| Sector (XLK) | 2.4% | 17.9% |
Fundamental Drivers
The -60.2% change in HIT stock from 4/30/2026 to 10/31/2026 was primarily driven by a -55.4% change in the company's P/S Multiple.| (LTM values as of) | 4302026 | 10312026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.45 | 0.58 | -60.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 33 | 33 | -1.5% |
| P/S Multiple | 2.5 | 1.1 | -55.4% |
| Shares Outstanding (Mil) | 57 | 63 | -9.4% |
| Cumulative Contribution | -60.2% |
Market Drivers
4/30/2026 to 10/31/2026| Return | Correlation | |
|---|---|---|
| HIT | -60.2% | |
| Market (SPY) | 5.4% | 4.6% |
| Sector (XLK) | 12.7% | -0.7% |
Fundamental Drivers
The -78.2% change in HIT stock from 10/31/2025 to 10/31/2026 was primarily driven by a -79.9% change in the company's P/S Multiple.| (LTM values as of) | 10312025 | 10312026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.65 | 0.58 | -78.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 27 | 33 | 23.0% |
| P/S Multiple | 5.5 | 1.1 | -79.9% |
| Shares Outstanding (Mil) | 55 | 63 | -11.9% |
| Cumulative Contribution | -78.2% |
Market Drivers
10/31/2025 to 10/31/2026| Return | Correlation | |
|---|---|---|
| HIT | -78.2% | |
| Market (SPY) | 11.7% | 16.6% |
| Sector (XLK) | 19.9% | 12.5% |
Fundamental Drivers
nullnull
Market Drivers
10/31/2023 to 10/31/2026| Return | Correlation | |
|---|---|---|
| HIT | ||
| Market (SPY) | 86.9% | 14.1% |
| Sector (XLK) | 122.8% | 10.7% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| HIT Return | - | - | - | 5% | -70% | -64% | -89% |
| Peers Return | 31% | 15% | -7% | -18% | -13% | 37% | 38% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 13% | 106% |
Monthly Win Rates [3] | |||||||
| HIT Win Rate | - | - | - | 100% | 67% | 40% | |
| Peers Win Rate | 52% | 60% | 43% | 48% | 55% | 50% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| HIT Max Drawdown | - | - | - | - | -93% | -74% | |
| Peers Max Drawdown | -18% | -18% | -21% | -33% | -43% | -28% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: UNH, ELV, CI, HUM, CNC.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 10/30/2026 (YTD)
About Health In Tech (HIT)
Health In Tech (HIT) is an insurance technology platform company dedicated to transforming the complex and often opaque healthcare industry. Its core mission is to remove friction and complexities by leveraging vertical integration, process simplification, automation, and digitalization. This approach is designed to streamline the underwriting, sales, and service processes for insurance companies, licensed brokers, and Third-Party Administrators (TPAs).
HIT's primary offering is a health insurance marketplace where insurance companies list various stop-loss policy options for self-funded benefits plans. Licensed brokers register on this platform to efficiently upload required information, select policies, and obtain bindable quotes, often within approximately two minutes. This rapid process enables brokers to swiftly sell these plans to small businesses. The marketplace further extends its utility by offering customizable solutions for health benefits plans, vendors, claims, and network services, allowing brokers to tailor offerings to their customers' specific requirements.
The company primarily serves small businesses seeking accessible self-funded benefits plans and stop-loss insurance, along with the licensed brokers, insurance carriers, and TPAs that facilitate these services. HIT's value proposition includes delivering meaningful cost savings for low-risk, small employers with comparatively healthy employees through its digital medical underwriting process. Moreover, it aims to provide significant time savings for employers, brokers, TPAs, and carriers by introducing greater transparency and efficiency into the healthcare insurance market through its innovative technology platforms.
AI Analysis | Feedback
Here are 1-3 brief analogies to describe Health In Tech (HIT):
- It's like a Kayak or Expedia for comparing and purchasing stop-loss health insurance policies for small businesses.
- Think of it as the Carvana for simplifying the online purchase of self-funded health plans and stop-loss insurance.
AI Analysis | Feedback
- Health Insurance Marketplace: An online platform where insurance companies list stop-loss policy options for self-funded benefits plans, and licensed brokers can obtain bindable quotes to sell to small businesses.
- Medical Underwriting Services: Technology-driven services that rapidly medically underwrite insurance policies and generate bindable quotes, streamlining the sales cycle.
- Customizable Benefits Plan Solutions: Services offered through the marketplace for tailoring health benefits plans, vendors, claims, and network services to suit customer needs.
AI Analysis | Feedback
Health In Tech (HIT) primarily serves other companies through its insurance technology platform. The company's major customers are categories of businesses rather than specific named entities provided in the description. These customer categories include:
- Insurance Companies (Carriers): These companies list various stop-loss policy options for self-funded benefits plans on HIT's marketplace.
- Licensed Brokers: Brokers register on the platform to access policy options, obtain bindable quotes, and sell them to small businesses.
- Third-Party Administrators (TPAs): TPAs are mentioned as benefiting from the platform's efficiencies and time savings, implying they are users or partners.
While the platform ultimately facilitates access to self-funded benefits plans and stop-loss insurance for small businesses, HIT's direct customers for its technology and services are the insurance carriers, licensed brokers, and TPAs.
AI Analysis | Feedback
AI Analysis | Feedback
Tim Johnson, Chief Executive Officer and Director
Mr. Johnson has served as Chief Executive Officer and as a member of Health In Tech's board of directors since its founding in 2014. He is also the Founder and Chairman of Health In Tech. Mr. Johnson has over 30 years of experience as an entrepreneur and has founded multiple successful companies in the medical insurance sectors. He possesses extensive knowledge in stop loss insurance and the self-funded benefits space. Mr. Johnson received his Master of Business Analytics from Missouri Western State College in 1988.
Julia Qian, Chief Financial Officer and Director
Ms. Qian has served as Chief Financial Officer since September 2022 and as a member of the board of directors since April 2024. Her responsibilities include financial accounting and capital markets. Before joining Health In Tech, Ms. Qian was Managing Director at The Blueshirt Group from December 2018 to September 2022. She also held various leadership roles at Citi from April 2012 to November 2018, including Senior Vice President of US retail banking and distribution, Strategy lead of Global Consumer Bank, and Regional director of secured lending Asia. Ms. Qian has over 20 years of leadership experience in global financial services, capital markets, and Fortune 100 companies.
Dustin Plantholt, Chief AI & Marketing Officer
Mr. Plantholt has been Chief AI & Marketing Officer since September 2025, previously serving as Chief Growth Officer from March 2025 to August 2025. He is responsible for leading enterprise-wide artificial intelligence initiatives and marketing strategy, driving Health In Tech's innovation and expansion. With over 20 years of experience in insurance, emerging technology, and media, Mr. Plantholt has successfully built, scaled, and exited multiple companies. He was named Entrepreneur's Metaverse Advisor of the Year in 2022.
Sri Rajagopalan, Chief Technology Officer
Mr. Rajagopalan has served as Health In Tech's Chief Technology Officer since February 2026, and prior to that, he was the Interim CTO from November 2025 to February 2026. He oversees end-to-end product engineering and enterprise platform operations, and is responsible for advancing Health In Tech's next-generation technology architecture, AI development roadmap, and embedding artificial intelligence, automation, and data intelligence across workflows. His previous roles include Senior Vice President of Software Engineering at Net Health and Senior Vice President of Platform Engineering and Enterprise Architecture at Zelis.
Jonathan Lockett, Chief Strategy Officer
Mr. Lockett has been Health In Tech's Chief Strategy Officer since March 2025. He previously served as Chief Operating Officer from January 2022 to March 2025 and initially joined the company as National Sales Director in June 2019.
AI Analysis | Feedback
Here are the key risks for Health In Tech (HIT):
- Market Adoption and Intense Competition: Health In Tech operates in the complex and heavily entrenched $4.5 trillion healthcare industry, aiming to disrupt it with innovation, process simplification, and digitalization. Established players benefit from years of claims history, significant operational scale, and strong brand recognition, creating substantial barriers for new entrants. There is a risk that insurance companies, licensed brokers, and small businesses may be slow to adopt HIT's marketplace and digital solutions, or that larger competitors could introduce similar offerings with greater resources. The company must effectively convince industry participants to shift from traditional methods to its platform, which requires overcoming inherent skepticism in a sector where people's lives are at stake.
- Reliance on Technology and Underwriting Accuracy: Health In Tech's core business model is dependent on its technology platform, particularly its "digital medical underwriting process" which aims to produce bindable quotes within approximately two minutes [cite: BACKGROUND]. The accuracy, robustness, and scalability of this underlying technology, including any integrated third-party AI, are critical. Inaccuracies in underwriting algorithms, which may be based on limited or biased historical data, could lead to incorrect risk assessments, resulting in significant financial losses, reputational damage, or an inability to attract profitable policies. Additionally, any failures, security vulnerabilities, or underperformance of these systems could severely undermine consumer trust and operational efficiency.
- Regulatory, Compliance, and Data Privacy Risks: Operating within the highly regulated healthcare and insurance sectors exposes Health In Tech to substantial regulatory and compliance risks. Regulations are constantly evolving and vary significantly by jurisdiction, making it challenging for underwriting systems to adapt quickly and potentially leading to non-compliance, fines, or legal issues. Furthermore, handling sensitive medical and financial data for underwriting and policy management creates significant data privacy and cybersecurity risks. Breaches of personally identifiable information (PII) or non-compliance with data protection laws (such as potential future AI regulations) could result in severe penalties, loss of trust, and damage to the company's reputation.
AI Analysis | Feedback
AI Analysis | Feedback
Health In Tech (HIT) operates within several addressable markets in the U.S. healthcare and insurance technology sectors.
-
Stop-Loss Insurance Market (U.S. / North America): The global stop-loss insurance market was valued at USD 27.9 billion in 2024 and is projected to grow to USD 48.35 billion by 2033. Another estimate values the global market at USD 30.4 billion in 2025, reaching an estimated USD 110.7 billion by 2035. North America held the largest share of the stop-loss insurance market in 2024. For context, the self-funded market, based on net employer stop-loss premiums, expanded to over $20 billion in 2019. The small and medium-sized enterprise segment within this market is experiencing the highest growth.
-
Self-Funded Health Plans for Small Businesses (U.S.): The small business health insurance market in the U.S., which includes self-funded and level-funded plans, was valued at approximately $1.46 billion (USD 1464.3 million) in 2025. This market is projected to grow at a Compound Annual Growth Rate (CAGR) of 5-7% from 2025 to 2033. In 2024, 20% of small businesses in the U.S. offered self-funded health insurance plans.
-
Insurtech Market (U.S.): The U.S. insurtech market has varying estimates for its size. One source valued it at USD 327.17 billion in 2026, with a projection to reach USD 426.96 billion by 2031. Other estimates include a valuation of USD 50.32 billion in 2024, expected to reach USD 71.10 billion by 2030, and an estimated USD 49.83 billion in 2024, projected to reach approximately USD 82.53 billion by 2035. Another report indicated the U.S. insurtech market generated revenue of approximately USD 2.29 billion (USD 2,291.7 million) in 2023 and is expected to reach approximately USD 42.15 billion (USD 42,154.6 million) by 2030.
AI Analysis | Feedback
Health In Tech (HIT) is poised for future revenue growth over the next 2-3 years, driven by several strategic initiatives and market dynamics:
- Expansion of Sales Distribution Network and Agency Partnerships: The company is actively expanding its network of licensed brokers, Third-Party Administrators (TPAs), and agencies. This expansion is leading to increased adoption of its eDIBS platform, resulting in more quotes being bound and sold in real time. For instance, the number of partners grew to 849 by September 30, 2025, a 57% year-over-year increase.
- Growth in Billed Enrolled Employees: A key driver of revenue is the increasing number of enrolled employees utilizing Health In Tech's platform. The company reported a significant rise in total billable enrolled employees, reaching 24,307 in Q1 2025, up from 20,802 in the same period last year. By Q3 2025, this number further increased to 25,248.
- Introduction and Enhancement of AI-Powered Products and Platform Features: Health In Tech is investing heavily in innovation, particularly in AI-backed underwriting and new platform features. The company has introduced significant product innovations, including a blockchain initiative and AI-driven services, and is preparing to launch its next-generation AI Engine. These technological advancements aim to streamline processes, remove complexities, and improve the overall efficiency of the healthcare and insurance industries.
- Strategic Market Expansion within the Self-Funded Employer Segment: Health In Tech is focused on expanding its presence within the underserved small and medium-sized self-funded employer market. This includes plans to expand into new U.S. regional markets, offering competitive and cost-effective solutions.
AI Analysis | Feedback
Share Issuance
- Health In Tech completed its Initial Public Offering (IPO) on December 24, 2024, raising $9.2 million through the sale of 2.3 million shares at $4.00 each.
- The total gross proceeds from the IPO could potentially increase to approximately $10.58 million if the underwriter exercises an option to purchase an additional 345,000 shares.
- In June 2025, directors received grants of restricted shares of Class A Common Stock under the company's Equity Incentive Plan, including 128,474 restricted shares each for Sanjay Shrestha and Chike Umemezia at $0.62 per share.
Inbound Investments
- The company secured $9.2 million in capital from its Initial Public Offering (IPO) on December 24, 2024.
- The net proceeds from the IPO are designated for purposes such as system enhancements, expanding service offerings, developing sales and distribution channels, talent retention, working capital, and other general corporate uses.
Capital Expenditures
- As of December 31, 2024, cash utilized in investing activities totaled $836,755, primarily allocated to software development.
- The company plans to continue investing in technology and innovation to advance automation and improve operational efficiency.
Peer Outperformance in Application Software
null| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Electronic Manufacturing Services | 10 | 23.5% | 116.3% | 232.6% | FLEX 597% · TTMI 526% · JBL 362% |
| Technology Distributors | 9 | 46.6% | 83.2% | 82.4% | AVT 162% · SNX 140% · CNXN 100% |
| Semiconductor Materials & Equipment | 28 | 41.2% | 75.7% | 59.3% | AXTI 574% · LRCX 346% · KLAC 345% |
| Communications Equipment | 36 | 2.6% | 86.8% | 51.0% | LITE 918% · AAOI 803% · ANET 559% |
| Electronic Components | 26 | 0.4% | 67.9% | 46.8% | CLS 2604% · BELFA 1204% · APH 332% |
| Semiconductors | 55 | 1.3% | 55.8% | 16.4% | MU 1211% · NVDA 704% · AVGO 570% |
| Technology Hardware, Storage & Peripherals | 21 | 3.7% | 100.8% | 2.6% | WDC 841% · SMCI 831% · DELL 744% |
| Electronic Equipment & Instruments | 27 | -6.9% | 33.7% | -1.1% | PI 158% · OSIS 114% · MIR 73% |
| Internet Services & Infrastructure | 6 | 5.8% | 60.2% | -10.1% | GDDY 69% · VRSN 40% · DOCN -8% |
| IT Consulting & Other Services | 30 | -26.7% | 2.5% | -24.6% | CHRN 378321% · APLD 280% · IBM 160% |
| Application Software ← | 126 | -17.2% | -2.8% | -49.0% | PLTR 611% · FROG 189% · AGYS 143% |
| Systems Software | 69 | -10.0% | 25.5% | -51.8% | ZETA 277% · CRWD 255% · CVLT 169% |
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Is Health In Tech Stock Built to Withstand a Pullback? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 352.18 |
| Mkt Cap | 64.1 |
| Rev LTM | 202,863 |
| Op Inc LTM | 5,216 |
| FCF LTM | 5,228 |
| FCF 3Y Avg | 3,116 |
| CFO LTM | 6,160 |
| CFO 3Y Avg | 4,064 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 8.7% |
| Rev Chg 3Y Avg | 10.8% |
| Rev Chg Q | 1.7% |
| QoQ Delta Rev Chg LTM | 0.4% |
| Op Inc Chg LTM | -10.4% |
| Op Inc Chg 3Y Avg | -9.5% |
| Op Mgn LTM | 2.0% |
| Op Mgn 3Y Avg | 2.2% |
| QoQ Delta Op Mgn LTM | 0.0% |
| CFO/Rev LTM | 3.0% |
| CFO/Rev 3Y Avg | 2.1% |
| FCF/Rev LTM | 2.6% |
| FCF/Rev 3Y Avg | 1.6% |
Price Behavior
| Market Price | $0.58 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 12/23/2024 | |
| Distance from 52W High | -80.4% | |
| 50 Days | 200 Days | |
| DMA Price | $0.81 | $1.15 |
| DMA Trend | down | down |
| Distance from DMA | -28.5% | -49.8% |
| 3M | 1YR | |
| Volatility | 67.0% | 93.4% |
| Downside Capture | 409.65 | 164.70 |
| Upside Capture | 38.94 | -32.89 |
| Correlation (S&P 500) | 12.2% | 17.4% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 2.11 | 0.88 | 1.15 | 0.25 | 1.21 | -0.28 |
| Up Beta | 17.77 | 1.47 | 0.87 | -0.59 | 2.51 | 0.58 |
| Down Beta | -1.21 | -0.46 | -0.65 | 0.32 | 1.86 | 0.43 |
| Up Capture | -47% | -63% | -1% | -55% | -23% | -2% |
| Bmk +ve Days | 12 | 18 | 28 | 62 | 130 | 427 |
| Stock +ve Days | 6 | 14 | 20 | 48 | 103 | 214 |
| Down Capture | 419% | 288% | 312% | 163% | 133% | 96% |
| Bmk -ve Days | 10 | 25 | 36 | 64 | 121 | 325 |
| Stock -ve Days | 16 | 29 | 40 | 67 | 130 | 228 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with HIT | |
|---|---|---|---|---|
| HIT | -79.4% | 93.4% | -1.25 | - |
| Sector ETF (XLK) | 18.6% | 27.1% | 0.60 | 12.8% |
| Equity (SPY) | 10.9% | 12.8% | 0.52 | 17.0% |
| Gold (GLD) | -2.0% | 28.6% | -0.08 | 0.9% |
| Commodities (DBC) | 48.2% | 20.6% | 1.79 | -3.4% |
| Real Estate (VNQ) | 10.2% | 13.7% | 0.45 | 4.7% |
| Bitcoin (BTCUSD) | -30.0% | 43.5% | -0.70 | 5.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with HIT | |
|---|---|---|---|---|
| HIT | -35.5% | 121.7% | -0.16 | - |
| Sector ETF (XLK) | 18.6% | 26.1% | 0.64 | 10.7% |
| Equity (SPY) | 12.2% | 17.1% | 0.53 | 14.1% |
| Gold (GLD) | 16.2% | 19.0% | 0.68 | 2.9% |
| Commodities (DBC) | 9.2% | 19.5% | 0.35 | 1.1% |
| Real Estate (VNQ) | 0.9% | 18.9% | -0.06 | 7.5% |
| Bitcoin (BTCUSD) | 4.9% | 51.6% | 0.28 | 10.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with HIT | |
|---|---|---|---|---|
| HIT | -19.7% | 121.7% | -0.16 | - |
| Sector ETF (XLK) | 23.7% | 25.1% | 0.86 | 10.7% |
| Equity (SPY) | 15.2% | 17.9% | 0.72 | 14.1% |
| Gold (GLD) | 11.4% | 16.5% | 0.56 | 2.9% |
| Commodities (DBC) | 8.2% | 18.1% | 0.37 | 1.1% |
| Real Estate (VNQ) | 5.3% | 20.7% | 0.21 | 7.5% |
| Bitcoin (BTCUSD) | 61.8% | 66.2% | 1.02 | 10.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 10/26/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/13/2026 | -5.2% | -3.8% | -16.1% |
| 5/13/2026 | -20.1% | -34.4% | -30.5% |
| 3/25/2026 | -0.5% | -20.3% | -17.0% |
| 11/12/2025 | -14.2% | -24.6% | -33.3% |
| 7/21/2025 | 25.2% | 21.5% | 137.8% |
| 4/14/2025 | 1.9% | -1.0% | 4.1% |
| SUMMARY STATS | |||
| # Positive | 2 | 1 | 2 |
| # Negative | 4 | 5 | 4 |
| Median Positive | 13.5% | 21.5% | 70.9% |
| Median Negative | -9.7% | -20.3% | -23.8% |
| Max Positive | 25.2% | 21.5% | 137.8% |
| Max Negative | -20.1% | -34.4% | -33.3% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/13/2026 | -5.2% | -3.8% | -16.1% |
| 5/13/2026 | -20.1% | -34.4% | -30.5% |
| 3/25/2026 | -0.5% | -20.3% | -17.0% |
| 11/12/2025 | -14.2% | -24.6% | -33.3% |
| 7/21/2025 | 25.2% | 21.5% | 137.8% |
| 4/14/2025 | 1.9% | -1.0% | 4.1% |
| SUMMARY STATS | |||
| # Positive | 2 | 1 | 2 |
| # Negative | 4 | 5 | 4 |
| Median Positive | 13.5% | 21.5% | 70.9% |
| Median Negative | -9.7% | -20.3% | -23.8% |
| Max Positive | 25.2% | 21.5% | 137.8% |
| Max Negative | -20.1% | -34.4% | -33.3% |
Recent Forward Guidance
Updated 10/26/2026Latest: Q2 2026 Earnings Reported 8/13/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | Reported | 45.00 Mil | 47.50 Mil | 50.00 Mil | 0 | Affirmed | Guidance: 47.50 Mil for 2026 | |
| 2026 Contracted Revenue | Reported | 9.70 Mil | 17.75 Mil | 25.80 Mil | ||||
| 2026 GAAP Revenue | Reported | 3.10 Mil | 5.70 Mil | 8.30 Mil | ||||
| 2027 GAAP Revenue | Reported | 6.60 Mil | 12.05 Mil | 17.50 Mil | ||||
Prior: Q1 2026 Earnings Reported 5/13/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | Reported | 45.00 Mil | 47.50 Mil | 50.00 Mil | 0 | Affirmed | Guidance: 47.50 Mil for 2026 | |
| 2026 Revenue Growth | Reported | 35.0% | 42.5% | 50.0% | 0 | Affirmed | Guidance: 42.5% for 2026 | |
Insider Activity
Updated 10/22/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Hasan, Zain Syed | Chief Growth Officer | Direct | Sell | 10192026 | 0.62 | 3,333 | 2,066 | 107,669 | Form |
| 2 | Hayes, Timothy | Direct | Sell | 9152026 | 0.89 | 12,000 | 10,716 | 97,141 | Form | |
| 3 | Hasan, Zain Syed | Chief Growth Officer | Direct | Sell | 9142026 | 0.92 | 11,667 | 10,734 | 173,460 | Form |
| 4 | Hayes, Timothy | Direct | Sell | 9112026 | 0.91 | 12,000 | 10,920 | 109,910 | Form | |
| 5 | Hayes, Timothy | Direct | Sell | 9112026 | 0.93 | 5,730 | 5,329 | 123,485 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Hasan, Zain Syed | Chief Growth Officer | Direct | Sell | 10192026 | 0.62 | 3,333 | 2,066 | 107,669 | Form |
| 2 | Hayes, Timothy | Direct | Sell | 9152026 | 0.89 | 12,000 | 10,716 | 97,141 | Form | |
| 3 | Hasan, Zain Syed | Chief Growth Officer | Direct | Sell | 9142026 | 0.92 | 11,667 | 10,734 | 173,460 | Form |
| 4 | Hayes, Timothy | Direct | Sell | 9112026 | 0.91 | 12,000 | 10,920 | 109,910 | Form | |
| 5 | Hayes, Timothy | Direct | Sell | 9112026 | 0.93 | 5,730 | 5,329 | 123,485 | Form |
Industry Resources
| Information Technology Resources |
| TechCrunch |
| Wired |
| CIO |
| MIT Technology Review |
| Gartner Insights |
| Ars Technica |
| Application Software Resources |
| Capterra |
| Software Advice |
| InfoWorld |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.